IL-7 in human health and disease

Seminars in Immunology

Volumn 24, Issue 3, 2012, Pages 218-224

  Lundström, Wangko ^a   Fewkes, Natasha M ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autoimmunity; Cancer; Interleukin 7; Interleukin 7 receptor

Indexed keywords

INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; RECOMBINANT INTERLEUKIN 7; THYMIC STROMAL LYMPHOPOIETIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOIMMUNITY; AUTOIMMUNITY; B CELL LEUKEMIA; B LYMPHOCYTE; BILIARY CIRRHOSIS; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CELL EXPANSION; CELL THERAPY; DRUG DOSE INCREASE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; SARCOIDOSIS; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ANIMALS; AUTOIMMUNITY; CELL DIFFERENTIATION; HOMEOSTASIS; HUMANS; INTERLEUKIN-7; LYMPHOCYTES; RECEPTORS, INTERLEUKIN-7;

EID: 84861195794     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2012.02.005     Document Type: Review

References (92)

1. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004, 22:625-655.
2. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998, 20:394-397.
3. Puck J.M., Deschenes S.M., Porter J.C., Dutra A.S., Brown C.J., Willard H.F., et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 1993, 2:1099-1104.
4. Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
5. Gaspar H.B., Cooray S., Gilmour K.C., Parsley K.L., Adams S., Howe S.J., et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for x-linked severe combined immunodeficiency. Sci Transl Med 2011, 3:97ra79.
6. Roifman C.M., Zhang J., Chitayat D., Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000, 96:2803-2807.
7. Giliani S., Mori L., de Saint Basile G., Le Deist F., Rodriguez-Perez C., Forino C., et al. Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev 2005, 203:110-126.
8. Grabstein K.H., Waldschmidt T.J., Finkelman F.D., Hess B.W., Alpert A.R., Boiani N.E., et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exp Med 1993, 178:257-264.
9. Kikuchi K., Lai A.Y., Hsu C.L., Kondo M. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med 2005, 201:1197-1203.
10. Namikawa R., Muench M.O., de Vries J.E., Roncarolo M.G. The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 1996, 87:1881-1890.
11. Dittel B.N., LeBien T.W. The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing CD34. J Immunol 1995, 154:58-67.
12. Parrish Y.K., Baez I., Milford T.A., Benitez A., Galloway N., Rogerio J.W., et al. IL-7 dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow. J Immunol 2009, 182:4255-4266.
13. Nodland S.E., Berkowska M.A., Bajer A.A., Shah N., de Ridder D., van Dongen J.J., et al. IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells. Blood 2011.
14. Malaspina A., Moir S., Chaitt D.G., Rehm C.A., Kottilil S., Falloon J., et al. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007, 109:2086-2088.
15. Malaspina A., Moir S., Ho J., Wang W., Howell M.L., O'Shea M.A., et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci USA 2006, 103:2262-2267.
16. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010, 16:727-735.
17. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
18. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
19. Fry T.J., Connick E., Falloon J., Lederman M.M., Liewehr D.J., Spritzler J., et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001, 97:2983-2990.
20. Maraskovsky E., Teepe M., Morrissey P.J., Braddy S., Miller R.E., Lynch D.H., et al. Impaired survival and proliferation in IL-7 receptor-deficient peripheral T cells. J Immunol 1996, 157:5315-5323.
21. Cupedo T., Crellin N.K., Papazian N., Rombouts E.J., Weijer K., Grogan J.L., et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009, 10:66-74.
22. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011.
23. Mavroukakis S.A., Muehlbauer P.M., White R.L., Schwartzentruber D.J. Clinical pathways for managing patients receiving interleukin 2. Clin J Oncol Nurs 2001, 5:207-217.
24. Kovacs J.A., Lempicki R.A., Sidorov I.A., Adelsberger J.W., Herpin B., Metcalf J.A., et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001, 194:1731-1741.
25. Guimond M., Veenstra R.G., Grindler D.J., Zhang H., Cui Y., Murphy R.D., et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 2009, 10:149-157.
26. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000, 1:426-432.
27. Goldrath A.W., Bevan M.J. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 1999, 11:183-190.
28. Tan J.T., Ernst B., Kieper W.C., LeRoy E., Sprent J., Surh C.D. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002, 195:1523-1532.
29. Ernst B., Lee D.S., Chang J.M., Sprent J., Surh C.D. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999, 11:173-181.
30. Hodge J.N., Srinivasula S., Hu Z., Read S.W., Porter B.O., Kim I., et al. Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance. Blood 2011.
31. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001, 24:363-373.
32. Schwartzentruber D.J. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001, 24:287-293.
33. Schwartzentruber D.J. High-dose interleukin-2 is an intensive treatment regardless of the venue of administration. Cancer J 2001, 7:103-104.
34. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006, 29:313-319.
35. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008, 205:1701-1714.
36. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.
37. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009, 119:997-1007.
38. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
39. Ammann A.J., Wara D.W., Pillarisetty R.J., Talal N. The prevalence of autoantibodies in T-cell, B-cell, and phagocytic immunodeficiency disorders. Clin Immunol Immunopathol 1979, 14:456-466.
40. Dias A.M., do Couto M.C., Duarte C.C., Ines L.P., Malcata A.B. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE. Ann N Y Acad Sci 2009, 1173:103-107.
41. Dhir V., Singh A.P., Aggarwal A., Naik S., Misra R. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus 2009, 18:785-791.
42. Goeb V., Salle V., Duhaut P., Jouen F., Smail A., Ducroix J.P., et al. Clinical significance of autoantibodies recognizing Sjogren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjogren's syndrome. Clin Exp Immunol 2007, 148:281-287.
43. King C., Ilic A., Koelsch K., Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117:265-277.
44. Gleeson P.A., Toh B.H., van Driel I.R. Organ-specific autoimmunity induced by lymphopenia. Immunol Rev 1996, 149:97-125.
45. McHugh R.S., Shevach E.M. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002, 168:5979-5983.
46. Krupica T., Fry T.J., Mackall C.L. Autoimmunity during lymphopenia: a two-hit model. Clin Immunol 2006, 120:121-128.
47. Ponchel F., Cuthbert R.J., Goëb V. IL-7 and lymphopenia. Clin Chim Acta 2011, 412:7-16.
48. Shinohara T., Nemoto Y., Kanai T., Kameyama K., Okamoto R., Tsuchiya K., et al. Upregulated IL-7 receptor alpha expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis. J Immunol 2011, 186:2623-2632.
49. Yamazaki M., Yajima T., Tanabe M., Fukui K., Okada E., Okamoto R., et al. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol 2003, 171:1556-1563.
50. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007, 39:1108-1113.
51. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007, 39:1083-1091.
52. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
53. Heron M., Grutters J.C., van Moorsel C.H., Ruven H.J., Huizinga T.W., van der Helm-van Mil A.H., et al. Variation in IL7R predisposes to sarcoid inflammation. Genes Immun 2009, 10:647-653.
54. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011.
55. Santiago J.L., Alizadeh B.Z., Martinez A., Espino L., de la Calle H., Fernandez-Arquero M., et al. Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia 2008, 51:1653-1658.
56. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007, 39:857-864.
57. Andersson A., Srivastava M.K., Harris-White M., Huang M., Zhu L., Elashoff D., et al. Role of CXCR3 ligands in IL-7/IL-7R{alpha}-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res 2011, 17:3660-3672.
58. Andersson A., Yang S.C., Huang M., Zhu L., Kar U.K., Batra R.K., et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009, 182:6951-6958.
59. Rose T., Lambotte O., Pallier C., Delfraissy J.F., Colle J.H. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol 2009, 182:7389-7397.
60. Hoe E., McKay F.C., Schibeci S.D., Gandhi K., Heard R.N., Stewart G.J., et al. Functionally significant differences in expression of disease-associated IL-7 receptor alpha haplotypes in CD4T cells and dendritic cells. J Immunol 2010, 184:2512-2517.
61. Maier L.M., Anderson D.E., Severson C.A., Baecher-Allan C., Healy B., Liu D.V., et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009, 182:1541-1547.
62. Crawley A.M., Faucher S., Angel J.B. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 2010, 184:4679-4687.
63. Cabrera R., Ararat M., Cao M., Xu Y., Wasserfall C., Atkinson M.A., et al. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci 2010, 55:484-495.
64. Bulanova E., Budagian V., Duitman E., Orinska Z., Krause H., Rückert R., et al. Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem 2007, 282:13167-13179.
65. Bolotin E., Annett G., Parkman R., Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999, 23:783-788.
66. Chung B., Dudl E., Toyama A., Barsky L., Weinberg K.I. Importance of interleukin-7 in the development of experimental graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:16-27.
67. Chung B., Dudl E.P., Min D., Barsky L., Smiley N., Weinberg K.I. Prevention of graft-versus-host disease by anti IL-7Ralpha antibody. Blood 2007, 110:2803-2810.
68. Sinha M.L., Fry T.J., Fowler D.H., Miller G., Mackall C.L. Interleukin 7 worsens graft-versus-host disease. Blood 2002, 100:2642-2649.
69. Dean R.M., Fry T., Mackall C., Steinberg S.M., Hakim F., Fowler D., et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol 2008, 26:5735-5741.
70. Thiant S., Yakoub-Agha I., Magro L., Trauet J., Coiteux V., Jouet J.P., et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010, 45:1546-1552.
71. Shamim Z., Ryder L.P., Christensen I.J., Toubert A., Norden J., Collin M., et al. Prognostic significance of interleukin-7 receptor-alpha gene polymorphisms in allogeneic stem-cell transplantation: a confirmatory study. Transplantation 2011, 91:731-736.
72. Bolotin E., Smogorzewska M., Smith S., Widmer M., Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 1996, 88:1887-1894.
73. Alpdogan O., Schmaltz C., Muriglan S.J., Kappel B.J., Perales M.A., Rotolo J.A., et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 2001, 98:2256-2265.
74. Rochman Y., Kashyap M., Robinson G.W., Sakamoto K., Gomez-Rodriguez J., Wagner K.U., et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci USA 2010, 107:19455-19460.
75. Brown V.I., Fang J., Alcorn K., Barr R., Kim J.M., Wasserman R., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003, 100:15113-15118.
76. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414-9418.
77. Kearney L., Gonzalez De Castro D., Yeung J., Procter J., Horsley S.W., Eguchi-Ishimae M., et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009, 113:646-648.
78. Gaikwad A., Rye C.L., Devidas M., Heerema N.A., Carroll A.J., Izraeli S., et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009, 144:930-932.
79. Bercovich D., Ganmore I., Scott L.M., Wainreb G., Birger Y., Elimelech A., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
80. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
81. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010, 107:252-257.
82. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
83. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
84. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., te Kronnie G., et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011, 208:901-908.
85. Lu X., Gross A.W., Lodish H.F. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem 2006, 281:7002-7011.
86. Constantinescu S.N., Huang L.J., Nam H., Lodish H.F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 2001, 7:377-385.
87. Tasian S.K., Doral M.Y., Wood B.L., Borowitz M.J., Collins-Underwood J.R., Harvey R.C., et al. Thymis stromal lymphopoietin stimulation of pediatric acute lymphoblastic leukemias with CRLF2 alterations induces JAK/STAT and PI3K phosphoignaling. Blood 2010, 116:182-183.
88. Barata J.T., Cardoso A.A., Nadler L.M., Boussiotis V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001, 98:1524-1531.
89. Barata J.T., Keenan T.D., Silva A., Nadler L.M., Boussiotis V.A., Cardoso A.A. Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica 2004, 89:1459-1467.
90. Touw I., Pouwels K., van Agthoven T., van Gurp R., Budel L., Hoogerbrugge H., et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990, 75:2097-2101.
91. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205:751-758.
92. Zenatti P.P., Ribeiro D., Li W., Zuurbier L., Silva M.C., Paganin M., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011.